Bioavailability Clinical Trial
— Bio-ßOfficial title:
Blood Bioavailability of Two Different Doses of a β-alanine Supplement
Verified date | December 2023 |
Source | Universidad Católica San Antonio de Murcia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to To study the blood bioavailability of a sustained-release β-alanine granulated supplement of two different doses (10 g and 20 g).
Status | Completed |
Enrollment | 12 |
Est. completion date | April 15, 2024 |
Est. primary completion date | March 18, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Men between 18 and 60 years old. - Cyclists with more than two years of cycling experience. - Bicycle training at least twice a week. Exclusion Criteria: - Suffer a lasting injury that prevents you from training in the month prior to surgery. - Subjects with a chronic illness. - Having consumed in the three months prior to the start of the study any ß-alanine supplement. - Making changes in diet or exercise during the study. - Inability to understand the informed consent form. - Consumption of other supplements that could alter the results of the study. |
Country | Name | City | State |
---|---|---|---|
Spain | Catholic University of Murcia | Murcia |
Lead Sponsor | Collaborator |
---|---|
Universidad Católica San Antonio de Murcia |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Aminoacids in plasma | The complete series of amino acids will be analyzed in plasma, after supplement intake, for 8 hours and at various times after product intakes. A bioavailability curve will be developed for each of these samples. | After the first intake of the product, samples will be taken at 15, 30, 45, 60 and 75 minutes. After the fourth and last product intake, samples will be taken at 15, 30, 45, 60, 75, 90, 120, 180 and 240 minutes. | |
Secondary | Paresthesia | It will be recorded by means of a visual analog scale (VAS), drawn with a continuous line of 10 centimeters where the left edge determines "no unusual sensation", translated to 0 in the recording of the data; and on the right edge "more intense sensation", translated to 10. | After the first intake of the product, samples will be taken at 15, 30, 45, 60 and 75 minutes. After the fourth and last product intake, samples will be taken at 15, 30, 45, 60, 75, 90, 120, 180 and 240 minutes. | |
Secondary | symptomatology - qualitative question | They should answer if they have felt at any time after the ingestion of ß-alanine any symptomatology such as: prickling, itching, tingling, numbness, chills and pain. | After the first intake of the product, samples will be taken at 15, 30, 45, 60 and 75 minutes. After the fourth and last product intake, samples will be taken at 15, 30, 45, 60, 75, 90, 120, 180 and 240 minutes. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06043739 -
Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02557139 -
Bioavailability of Belumosudil (KD025) in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT02010944 -
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
|
Phase 1 | |
Not yet recruiting |
NCT01136551 -
Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A
|
N/A | |
Completed |
NCT01208155 -
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
|
Phase 1 | |
Completed |
NCT04097808 -
Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects
|
N/A | |
Active, not recruiting |
NCT06098001 -
Bioavailability Study of Hemp Phenolics
|
N/A | |
Completed |
NCT01912144 -
Absorption of Phenolic Acids From Coffee in Humans
|
N/A | |
Completed |
NCT03915626 -
Effect of Heat on Rivastigmine TDS Products
|
Early Phase 1 | |
Completed |
NCT01464450 -
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT01448772 -
Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT01181973 -
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00858767 -
Arabic Gum-Absorption Study
|
N/A | |
Completed |
NCT04113564 -
Absolute Oral Bioavailability of Remimazolam
|
Phase 1 | |
Completed |
NCT04645394 -
Bioavailability of Anthocyanins From Aronia Extract in Healthy Men - a Pilot Study
|
N/A | |
Completed |
NCT03485885 -
Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects
|
||
Completed |
NCT05840848 -
Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males
|
N/A | |
Completed |
NCT02986529 -
A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects
|
Phase 1 | |
Completed |
NCT01789359 -
Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding
|
N/A | |
Completed |
NCT01638143 -
Bio-equivalence Study
|
N/A |